Trinity Capital Inc. Invests $35 Million in Neuros Medical to Enhance Pain Management Innovations

Trinity Capital Inc. Makes Significant Investment in Neuros Medical

Trinity Capital Inc., a prominent international asset management firm, has recently announced a commitment of $35 million in growth capital directed at Neuros Medical, Inc., a cutting-edge company that specializes in providing solutions for chronic post-amputation pain. As the medical technology landscape continues to evolve, this strategic investment aims to facilitate the adoption of Neuros Medical's Altius Direct Electrical Nerve Stimulation System, which is designed to assist individuals in managing debilitating pain after amputations.

Neuros Medical's Altius system is one of the first of its kind to receive FDA approval, marking a significant stride in the medical technology realm. This innovative device targets pain by interrupting the peripheral nerve signals that cause phantom limb and residual limb pain. By empowering patients with the ability to self-activate therapy as needed, the Altius system presents a unique alternative to traditional opioid-based pain management methods, which unfortunately have been the mainstay in treating such conditions.

Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, commented on the importance of this investment by stating, "Neuros Medical has reached an important inflection point as their technology moves into real-world adoption. We are proud to continue to support their team as they expand access to a differentiated therapy that addresses a significant need within the life sciences ecosystem." This endorsement underscores the confidence that Trinity Capital has in the potential impact of Neuros Medical's technologies on improving patient outcomes in pain management.

The newly allocated funds will facilitate Neuros Medical in scaling the commercialization of the Altius system while also paving the way for expansion into new markets. This move comes at a crucial time when the demand for effective pain relief solutions is growing, particularly among the over two million patients currently living with limb loss in the United States. With approximately 300,000 lower limb amputations performed annually, the need for innovative pain management therapies has never been more pressing.

David Veino, President and CEO of Neuros Medical, expressed gratitude towards Trinity Capital, stating, "We appreciate the continued partnership from Trinity. The Trinity team has been an important partner prior to us achieving FDA approval and will remain an important partner as we expand. This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase of its mission to relieve pain and restore life for this underserved patient population."

Neuros Medical's commitment to improving the lives of amputees is evident in its mission to provide unparalleled pain management solutions. The Altius system is designed specifically as an aid in addressing chronic, intractable pain, making it a significant advancement in the medical technology landscape. As the company positions itself for growth, the collaboration with Trinity Capital signifies a strategic alignment aimed at addressing unmet medical needs through innovative solutions.

Trinity Capital Inc. stands as a leading player in the alternative asset management sector, having deployed over $5.5 billion across more than 463 investments since its inception in 2008. The company's commitment to providing tailored financial solutions for innovative companies reflects its strategic approach to fostering growth in various industries, including life sciences.

As both companies move forward, the collaboration between Trinity Capital and Neuros Medical is sure to have a profound impact on the future of pain management therapies. With advancements in neuromodulation technology leading the way in addressing pain, patients suffering from post-amputation pain can look forward to more effective and accessible treatment options in the near future.

In conclusion, the partnership not only symbolizes a significant financial commitment but also represents a shared vision for revolutionizing pain management solutions, ultimately providing relief and improving the quality of life for countless individuals affected by limb loss.